Gabapentin for Neuropathy: Does It Actually Work?

Gabapentin does reduce neuropathic pain for a meaningful number of people, but it helps fewer patients than many expect, and a surprising number of those who take it never reach the dose where it starts to work. In the best-studied conditions, roughly one in six to one in eight people who take gabapentin get at least a 50 percent reduction in pain. That is a real effect, confirmed across multiple randomized trials, yet it also means most people on the drug see a more modest benefit or none at all. The gap between how widely gabapentin is prescribed and how strong the evidence actually is varies enormously depending on the type of neuropathy in question.

What Gabapentin Does in the Nervous System

Gabapentin was originally designed as an anti-seizure drug, and its pain-relieving properties were discovered somewhat by accident during clinical use. The drug binds to a specific part of voltage-gated calcium channels in the nervous system, a subunit called alpha-2-delta-1. When nerve injury occurs, the body upregulates these subunits, which amplifies pain signaling. By latching onto alpha-2-delta-1, gabapentin reduces the release of excitatory chemical messengers that would otherwise keep pain circuits firing. Molecular and transgenic studies strongly support this as the sole target responsible for gabapentin’s painkilling effects, even though other mechanisms have been proposed over the years.¹

This mechanism matters practically because gabapentin is not a general painkiller. It does not work the way ibuprofen or acetaminophen works, and it does not activate opioid receptors. It targets a specific change that happens after nerve damage, which is why it can help with neuropathic pain but generally does nothing for, say, a sprained ankle or a headache. If the nerve injury has not caused the upregulation of those calcium channel subunits, gabapentin has little to bind to and little to do.²

Where the Evidence Is Strongest

The two conditions where gabapentin has the best track record are postherpetic neuralgia (the nerve pain that lingers after shingles) and painful diabetic neuropathy. These are the indications that originally earned gabapentin its FDA approval for neuropathic pain, and they remain the conditions with the deepest pool of randomized trial data.

In diabetic neuropathy, one of the landmark trials compared gabapentin (titrated up to 3,600 mg per day) against placebo over eight weeks. Patients on gabapentin saw their average daily pain score drop from about 6.4 to 3.9 on a ten-point scale, while placebo patients went from 6.5 down to only 5.1. All secondary measures of pain also favored gabapentin.³ For postherpetic neuralgia, a separate landmark trial showed a number needed to treat of about 3.2, meaning roughly one in three patients got a meaningful benefit above what placebo provided.⁴

A meta-analysis pooling data from several randomized controlled trials confirmed that gabapentin significantly reduced postherpetic neuralgia compared with placebo and that patients on gabapentin were about 60 percent more likely to achieve at least a 50 percent pain reduction.⁵ Across these two approved conditions at doses of 1,200 mg or more per day, the number needed to treat ranges from about six for diabetic neuropathy to about eight for postherpetic neuralgia when the endpoint is a 50 percent drop in pain intensity. Beyond pain reduction, gabapentin also relieved symptoms like burning, shooting pain, and allodynia (pain from normally non-painful touch).⁶

The Dosing Problem Most People Never Hear About

Here is where gabapentin’s reputation starts to come apart for many patients: the drug has a quirk in how the body absorbs it that makes reaching an effective dose genuinely tricky. Unlike most medications, gabapentin relies on a saturable transport system in the gut. At low doses, absorption is decent. As the dose climbs, the transporter gets overwhelmed, and a smaller and smaller fraction of each pill actually makes it into the bloodstream. Bioavailability drops from roughly 74 percent at 100 mg down to about 36 percent at 1,600 mg.⁷ In practical terms, doubling the dose does not double the drug in your blood. At higher doses, the absolute bioavailability falls from around 60 percent at 900 mg per day to about 33 percent at 3,600 mg per day.⁸

This creates a clinical problem. Most trials that showed gabapentin working used doses of 1,800 to 3,600 mg per day, split into three daily doses. But in real-world practice, patients are often started low and left there. A study of real-world prescribing for postherpetic neuralgia found the average daily dose was only 826 mg, and only about 14 percent of patients ever reached the target dose of 1,800 mg per day.⁹ So a large chunk of patients who “tried gabapentin and it didn’t work” may never have actually received an adequate dose. Side effects like drowsiness and dizziness often slow the titration process, and some prescribers simply never push the dose high enough. If you or someone you know abandoned gabapentin after a few weeks on a low dose, the drug may not have gotten a fair trial.

How Gabapentin Compares to Pregabalin

Pregabalin (Lyrica) is essentially gabapentin’s younger sibling. Both drugs bind to the same alpha-2-delta-1 target, but pregabalin has a cleaner pharmacokinetic profile. It is absorbed more rapidly, reaching peak blood levels within about an hour compared to three to four hours for gabapentin. More importantly, pregabalin’s absorption is linear: if you double the dose, blood levels roughly double. Its bioavailability stays at 90 percent or above regardless of the dose, which makes it far more predictable than gabapentin.⁸

In head-to-head comparisons, pregabalin at 450 mg per day appears to reduce neuropathic pain comparably to gabapentin’s predicted maximum effect. A trial comparing pregabalin, gabapentin, and amitriptyline (a tricyclic antidepressant also used for neuropathic pain) found that pregabalin and gabapentin performed similarly for pain relief, though their side-effect profiles differed somewhat. Pregabalin caused more dizziness and sedation, while amitriptyline was more likely to cause dry mouth and constipation.¹⁰ The practical trade-off often comes down to cost and convenience. Gabapentin went generic years ago and is inexpensive, but requires three-times-daily dosing and the absorption hassle. Pregabalin is also now available as a generic in many markets, which has narrowed the price gap, and it can be dosed twice daily with more predictable results.

Where the Evidence Gets Thin

Gabapentin is prescribed for a remarkably wide range of conditions beyond its FDA-approved neuropathic pain indications. A review of off-label use noted that gabapentin is widely prescribed for conditions like migraine, fibromyalgia, mental illness, and substance dependence, but that reviews of these off-label uses have found modest to no effect on relevant outcomes. The review pointed out that high-quality evidence for these uses has often been overshadowed by uncontrolled studies and limited case reports.¹¹ A study at a large academic medical center found that while about two-thirds of gabapentinoid prescriptions had at least some supporting evidence, nearly 29 percent had conflicting or insufficient evidence behind them.¹²

One off-label use that gets a lot of attention is chemotherapy-induced peripheral neuropathy. This is the nerve damage that certain cancer drugs cause, and it affects a large number of cancer survivors. Unfortunately, a systematic review and meta-analysis found limited evidence to support gabapentinoids for this condition. In the prevention setting, they did not significantly prevent the neuropathy from developing. In the treatment setting, studies have been inconsistent, without definitive benefits over placebo.¹³ This is genuinely frustrating for patients and oncologists, because effective treatments for chemotherapy-induced neuropathy remain scarce.

Another area where prescribing has raced ahead of the science is the use of gabapentinoids in Nepal and other settings. One cross-sectional study found that over 96 percent of gabapentinoid prescriptions were off-label by FDA indications.¹⁴ While off-label prescribing is not inherently wrong and sometimes reflects legitimate clinical judgment, the sheer scale suggests that gabapentin has acquired a reputation as a safe, catch-all nerve drug that exceeds what the evidence actually supports.

Side Effects and What to Expect

The most common side effects of gabapentin are drowsiness, dizziness, and fatigue. These tend to be worst during the first few weeks of treatment and when the dose is being increased. They are the main reason many patients stall out at low doses. A pooled analysis of three clinical trials in postherpetic neuralgia patients found that discontinuation rates were actually comparable between people taking gabapentin and those on placebo, which suggests that while side effects are common, they are usually manageable enough that people stay on the drug.¹⁵

One side effect that patients sometimes welcome is improved sleep. Neuropathic pain frequently disrupts sleep, and a review of the relationship between neuropathic pain and sleep found that gabapentin has a positive effect on comorbid sleep disturbances.¹⁶ Whether this is a direct sedative effect or simply what happens when pain is reduced enough to let you sleep is debated, but either way, many patients report better rest.

Weight gain is another side effect that comes up in longer-term use and can be significant enough to bother people. Peripheral edema (swelling in the hands and feet) also occurs. Cognitive fogginess, described by patients as difficulty concentrating or feeling mentally slow, is reported frequently enough that it deserves mention, even though it is harder to quantify than drowsiness in a clinical trial.

The Opioid Safety Concern

One safety issue has become increasingly important as awareness has grown: the interaction between gabapentin and opioids. A large population-based study found that people co-prescribed opioids and gabapentin had roughly 49 percent higher adjusted odds of opioid-related death compared with people prescribed opioids alone. The risk was dose-dependent. Moderate and high doses of gabapentin both showed about a 56 to 58 percent increase in the odds of dying from an opioid-related cause.¹⁷

When benzodiazepines are added to that combination, the risks climb further. A nested case-control study found that people taking all three drug classes together had significantly higher odds of respiratory depression and overdose compared with those on opioids alone.¹⁸ This is a real concern because gabapentin is frequently prescribed alongside opioids, sometimes specifically to reduce opioid doses. The irony is that the combination intended to lower opioid risk may introduce its own dangers. If you are taking both, your prescriber should be aware and should be weighing the risks explicitly.

Kidney Function and Dose Adjustments

Gabapentin is cleared almost entirely by the kidneys. It is not broken down by liver enzymes, which means it avoids the common drug-drug interaction problems that plague many medications. But the flip side is that if your kidneys are not working well, gabapentin accumulates. Its elimination is directly proportional to creatinine clearance, the standard measure of kidney function.¹⁹

For people with reduced kidney function, standard doses can lead to toxicity, causing severe drowsiness, confusion, or even respiratory depression. Case reports have documented gabapentin toxicity in kidney failure patients requiring dialysis to clear the drug.²⁰ This is particularly relevant for people with diabetic neuropathy, since diabetes is also the leading cause of chronic kidney disease. A patient taking gabapentin for diabetic nerve pain may see their kidney function decline over years, meaning the same dose that was safe initially can become dangerous without adjustment. Dose reductions are standard practice when kidney function drops, but they require monitoring that does not always happen in routine care.

Misuse and the Changing Regulatory Landscape

Gabapentin was long considered to have minimal abuse potential, which is one reason it was never classified as a controlled substance at the federal level in the United States (though some states have since scheduled it). That perception has shifted. At supratherapeutic doses, gabapentin can produce euphoria and a high that some describe as similar to a mild opioid or benzodiazepine. A review identified that gabapentin misuse rates were about 1 percent in the general population but about 22 percent among people in drug abuse treatment programs. Cases of addiction overwhelmingly occurred in patients with a prior history of substance use disorders, and the doses involved were typically above 3,000 mg per day.²¹

Gabapentin misuse most commonly occurs alongside other substances, particularly opioids, and may be pursued for euphoric effects, to enhance the high from other drugs, or to self-treat withdrawal symptoms, pain, or insomnia. Significant withdrawal effects can occur on abrupt discontinuation, which can be a surprise for patients and prescribers who assumed gabapentin was too “mild” for that.²² The widespread prescribing of gabapentin, partly driven by a desire to avoid opioids, has paradoxically created a new reservoir of a drug with its own misuse potential.²³ Several U.S. states and other countries have responded by reclassifying gabapentin as a controlled substance, adding prescription monitoring requirements.

The Placebo Problem in Neuropathic Pain Trials

One reason the evidence for gabapentin sometimes looks less impressive than expected is the surprisingly strong placebo response in neuropathic pain trials. Pain is inherently subjective, and clinical trials of analgesics consistently see high and variable placebo response rates. Neuropathic pain was once assumed to be relatively resistant to placebo effects because it is driven by measurable nerve damage, but recent experience in large trials suggests otherwise. Large placebo responses make it harder for any active drug to separate itself from the control group, and they may partially explain why gabapentin’s numbers-needed-to-treat look modest even in conditions where it clearly works for some patients. It also means that some of the benefit patients experience on gabapentin includes a placebo component, which is not a reason to stop taking it if it helps, but is worth understanding.

Gabapentin in Veterinary Medicine

Gabapentin has found a second life in veterinary practice, where it is used off-label in dogs, cats, and horses. In animals, it serves as both an anticonvulsant and a treatment for neuropathic pain, and it has become popular as a mild anxiolytic, particularly for cats before veterinary visits. A review of its veterinary pharmacokinetics noted that it is used in combination with other treatments to control seizures when other drugs are no longer effective or have become toxic, as well as for neuropathic pain and anxiety.²⁴ Absorption and metabolism differ across species, so veterinary doses are not interchangeable with human ones, but the underlying mechanism of action appears to be the same. The drug’s relatively wide safety margin in animals has made it a go-to option in situations where other pain medications carry more risk.